Form 8-K - Current report:
SEC Accession No. 0001711279-23-000033
Filing Date
2023-05-11
Accepted
2023-05-11 07:33:53
Documents
14
Period of Report
2023-05-11
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K krys-20230511.htm   iXBRL 8-K 41631
2 EX-99.1 isid2023-finalposterpdf_.htm EX-99.1 8125
6 GRAPHIC isid2023-finalposterpdf_001.jpg GRAPHIC 346445
  Complete submission text file 0001711279-23-000033.txt   658456

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT krys-20230511.xsd EX-101.SCH 1914
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT krys-20230511_lab.xml EX-101.LAB 22164
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT krys-20230511_pre.xml EX-101.PRE 11598
8 EXTRACTED XBRL INSTANCE DOCUMENT krys-20230511_htm.xml XML 9791
Mailing Address 2100 WHARTON STREET SUITE 701 PITTSBURGH PA 15203
Business Address 2100 WHARTON STREET SUITE 701 PITTSBURGH PA 15203 (412) 586-5830
Krystal Biotech, Inc. (Filer) CIK: 0001711279 (see all company filings)

EIN.: 821080209 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38210 | Film No.: 23908850
SIC: 2836 Biological Products, (No Diagnostic Substances)